$5.12 +0.14 (2.81%)

Synchronoss Technologies Inc Common Stock (SNCR)

Synchronoss Technologies Inc (SNCR) is a global provider of cloud, messaging, and digital transformation solutions for telecommunications and digital service providers. The company offers platforms and services that enable seamless customer engagement, device management, and revenue growth, supporting carriers and enterprises in delivering innovative digital experiences.

🚫 Synchronoss Technologies Inc Common Stock does not pay dividends

Company News

Analysts Think These Stocks Could More Than Double
Investing.com β€’ Nathan Reiff β€’ October 22, 2025

Analysts highlight three stocks with significant potential growth: SharpLink Gaming, Townsquare Media, and Synchronoss Technologies, each with unique market strategies and bullish price targets.

Synchronoss ε–εΎ—ζ­η›Ÿ-ηΎŽεœ‹θ³‡ζ–™η§ιš±ζ‘†ζžΆθͺθ­‰
GlobeNewswire Inc. β€’ Domenick Cilea β€’ June 25, 2025

Synchronoss Technologies has obtained EU-U.S. Data Privacy Framework (DPF) certification, enabling secure cross-border personal data transfers between the EU and US while complying with GDPR regulations.

Synchronoss (SNCR) Stock Falls Amid Market Uptick: What Investors Need to Know
Zacks Investment Research β€’ Zacks Equity Research β€’ June 27, 2024

In the closing of the recent trading day, Synchronoss (SNCR) stood at $7.87, denoting a -1.63% change from the preceding trading day.

Insiders Buying Agree Realty And 3 Other Stocks
Benzinga β€’ Avi Kapoor β€’ February 26, 2024

Although U.S. stocks closed mixed on Friday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for mak...

Bed Bath & Beyond's stock gives up gains after proceeds from Feb. equity offering rise, and CrowdStrike gains after earnings beat
MarketWatch β€’ MarketWatch β€’ March 8, 2023

Tesla's stock drops again, Fresh Track Therapeutics' shares soars upon initial clinical trial results